Literature DB >> 25234679

Paclitaxel-coated balloon angioplasty versus drug-eluting stenting for the treatment of infrapopliteal long-segment arterial occlusive disease: the IDEAS randomized controlled trial.

Dimitris Siablis1, Panagiotis M Kitrou1, Stavros Spiliopoulos1, Konstantinos Katsanos2, Dimitris Karnabatidis3.   

Abstract

OBJECTIVES: This study sought to report the results of a prospective randomized controlled trial comparing paclitaxel-coated balloons (PCB) versus drug-eluting stents (DES) in long infrapopliteal lesions.
BACKGROUND: DES have an established role in the treatment of short infrapopliteal lesions, whereas there is increasing evidence for the use of PCB in longer below-the-knee lesions.
METHODS: Inclusion criteria were patients with Rutherford classes 3 to 6 and angiographically documented infrapopliteal disease with a minimum lesion length of 70 mm. The primary endpoint was target lesion restenosis >50% assessed by digital angiography at 6 months. Secondary endpoints included immediate post-procedure stenosis and target lesion revascularization.
RESULTS: Fifty patients were randomized to undergo infrapopliteal PCB angioplasty (25 arteries in 25 limbs; PCB group) or primary DES placement (30 arteries in 27 limbs; DES group). Immediate residual post-procedure stenosis was significantly lower in DES (9.6 ± 2.2% vs. 24.8 ± 3.5% in PCB; p < 0.0001). At 6 months, 5 patients died (2 in PCB vs. 3 in DES; p = 1.00) and 3 suffered a major amputation (1 in PCB vs. 2 in DES; p = 1.00). In total, 44 angiograms were evaluable with quantitative vessel analysis. Binary (>50%) angiographic restenosis rate was significantly lower in DES (7 of 25 [28%] vs. 11 of 19 [57.9%] in PCB; p = 0.0457). There were no significant differences with regard to target lesion revascularization (2 of 26 [7.7%] in DES vs. 3 of 22 [13.6%] in PCB; p = 0.65). Positive vessel wall remodeling was observed in 3 cases in the PCB arm (3 of 19 [(15.8%)] vs. 0 of 19 [0%] in DES; p = 0.07).
CONCLUSIONS: Compared with PCB in long infrapopliteal lesions, DES are related with significantly lower residual immediate post-procedure stenosis and have shown significantly reduced vessel restenosis at 6 months. PCB may produce positive vessel remodeling. (Infrapopliteal Drug-Eluting Angioplasty Versus Stenting [IDEAS-I]; NCT01517997).
Copyright © 2014 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  drug-eluting stents; infrapopliteal lesions; neointimal hyperplasia; paclitaxel-coated balloons; restenosis

Mesh:

Substances:

Year:  2014        PMID: 25234679     DOI: 10.1016/j.jcin.2014.04.015

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  26 in total

1.  An Update on Methods for Revascularization and Expansion of the TASC Lesion Classification to Include Below-the-Knee Arteries: A Supplement to the Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II): The TASC Steering Comittee(.).

Authors:  Michael R Jaff; Christopher J White; William R Hiatt; Gerry R Fowkes; John Dormandy; Mahmood Razavi; Jim Reekers; Lars Norgren
Journal:  Ann Vasc Dis       Date:  2015-10-23

Review 2.  Endovascular Treatment of Infrapopliteal Peripheral Artery Disease.

Authors:  Ehrin J Armstrong; Kalkidan Bishu; Stephen W Waldo
Journal:  Curr Cardiol Rep       Date:  2016-04       Impact factor: 2.931

Review 3.  Drug-Eluting Balloons and Drug-Eluting Stents in the Treatment of Peripheral Vascular Disease.

Authors:  Jonathan Lindquist; Kristofer Schramm
Journal:  Semin Intervent Radiol       Date:  2019-02-05       Impact factor: 1.513

Review 4.  2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Marie D Gerhard-Herman; Heather L Gornik; Coletta Barrett; Neal R Barshes; Matthew A Corriere; Douglas E Drachman; Lee A Fleisher; Francis Gerry R Fowkes; Naomi M Hamburg; Scott Kinlay; Robert Lookstein; Sanjay Misra; Leila Mureebe; Jeffrey W Olin; Rajan A G Patel; Judith G Regensteiner; Andres Schanzer; Mehdi H Shishehbor; Kerry J Stewart; Diane Treat-Jacobson; M Eileen Walsh
Journal:  Circulation       Date:  2016-11-13       Impact factor: 29.690

Review 5.  The Contemporary Role of Stents and Angioplasty for the Treatment of Infrapopliteal Disease in Critical Limb Ischemia.

Authors:  Tarek A Hammad; Anand Prasad
Journal:  Curr Cardiol Rep       Date:  2017-07       Impact factor: 2.931

6.  Endovascular Devices and Revascularization Techniques for Limb-Threatening Ischemia in Individuals With Diabetes.

Authors:  Jayer Chung
Journal:  J Diabetes Sci Technol       Date:  2017-03-28

7.  Network meta-analysis of balloon angioplasty, nondrug metal stent, drug-eluting balloon, and drug-eluting stent for treatment of infrapopliteal artery occlusive disease.

Authors:  Yaowen Xiao; Zhong Chen; Yaoguo Yang; Lei Kou
Journal:  Diagn Interv Radiol       Date:  2016 Sep-Oct       Impact factor: 2.630

8.  Asia-Pacific Consensus Statement on the Management of Peripheral Artery Disease: A Report from the Asian Pacific Society of Atherosclerosis and Vascular Disease Asia-Pacific Peripheral Artery Disease Consensus Statement Project Committee.

Authors:  Maria Teresa B Abola; Jonathan Golledge; Tetsuro Miyata; Seung-Woon Rha; Bryan P Yan; Timothy C Dy; Marie Simonette V Ganzon; Pankaj Kumar Handa; Salim Harris; Jiang Zhisheng; Ramakrishna Pinjala; Peter Ashley Robless; Hiroyoshi Yokoi; Elaine B Alajar; April Ann Bermudez-Delos Santos; Elmer Jasper B Llanes; Gay Marjorie Obrado-Nabablit; Noemi S Pestaño; Felix Eduardo Punzalan; Bernadette Tumanan-Mendoza
Journal:  J Atheroscler Thromb       Date:  2020-07-04       Impact factor: 4.928

9.  Management of Critical Limb Ischemia.

Authors:  Scott Kinlay
Journal:  Circ Cardiovasc Interv       Date:  2016-02       Impact factor: 6.546

Review 10.  [Drug-coated balloons in the treatment of peripheral artery disease (PAD). History and current level of evidence].

Authors:  M Herten; S Stahlhoff; B Imm; E Schönefeld; A Schwindt; G B Torsello
Journal:  Radiologe       Date:  2016-03       Impact factor: 0.635

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.